Compare Amplitude Inc (AMPL) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplitude Inc vs BioNano Genomics Inc — how do they compare? Amplitude Inc trades at $12.38 (market cap $1.59B), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: Amplitude Inc is far larger — about 116.4× BioNano Genomics Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| AMPL | BNGO | |
|---|---|---|
Market Cap | $1.59B | $13.66M |
Sector | Technology | Health |
52-Week High | $12.69 | $4.92 |
52-Week Low | $5.61 | $1.06 |
Enterprise Value | $1.45B | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPL trades at $12.37, up 1.48% today, with a bullish technical signal from moving averages. Revenue grew to $343.21M in 2025, but net losses persist at -$88.54M. Analyst consensus is bullish with a $12.08 price target, supported by enterprise and AI-driven growth initiatives highlighted in recent earnings calls. The stock shows strong institutional buy ratings despite negative profitability metrics.
Outlook remains cautiously optimistic due to revenue growth and AI expansion, but risks include sustained losses, cash flow deficits, and ongoing legal investigations. The stock's valuation at P/S 4.49 may appeal if profitability improves, yet high P/B 11.64 signals premium pricing relative to book value.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
